NASDAQ:CALC CalciMedica (CALC) Stock Price, News & Analysis $3.94 +0.06 (+1.55%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.91▼$3.9950-Day Range$3.15▼$5.6952-Week Range$1.75▼$8.38Volume1,922 shsAverage Volume34,999 shsMarket Capitalization$42.36 millionP/E RatioN/ADividend YieldN/APrice Target$20.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get CalciMedica alerts: Email Address CalciMedica MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside424.5% Upside$20.67 Price TargetShort InterestHealthy0.51% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.06Based on 3 Articles This WeekInsider TradingAcquiring Shares$43,371 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.08) to ($1.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.76 out of 5 starsMedical Sector248th out of 936 stocksPharmaceutical Preparations Industry111th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingCalciMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCalciMedica has only been the subject of 3 research reports in the past 90 days.Read more about CalciMedica's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.51% of the float of CalciMedica has been sold short.Short Interest Ratio / Days to CoverCalciMedica has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CalciMedica has recently decreased by 68.68%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCalciMedica does not currently pay a dividend.Dividend GrowthCalciMedica does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CALC. Previous Next 3.4 News and Social Media Coverage News SentimentCalciMedica has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CalciMedica this week, compared to 1 article on an average week.Search Interest9 people have searched for CALC on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CalciMedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $43,371.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders53.30% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about CalciMedica's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CalciMedica are expected to grow in the coming year, from ($2.08) to ($1.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CalciMedica is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CalciMedica is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalciMedica has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CalciMedica's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About CalciMedica Stock (NASDAQ:CALC)CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Read More CALC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CALC Stock News HeadlinesJuly 2, 2024 | insidertrades.comInsider Buying: CalciMedica, Inc. (NASDAQ:CALC) Director Purchases 8,443 Shares of StockJune 29, 2024 | insidertrades.comCalciMedica, Inc. (NASDAQ:CALC) Insider Buys $16,100.00 in StockJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 20, 2024 | finance.yahoo.comCalciMedica, Inc. (CALC)July 9, 2024 | prnewswire.comCalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)July 8, 2024 | prnewswire.comCalciMedica Announces Presentations at Two Upcoming Healthcare Investment ConferencesJuly 1, 2024 | prnewswire.comCalciMedica Set to Join Russell Microcap® IndexJune 27, 2024 | prnewswire.comCalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 26, 2024 | prnewswire.comCalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)May 28, 2024 | investorplace.comCALC Stock Earnings: CalciMedica Beats EPS for Q1 2024May 22, 2024 | uk.investing.comOppenheimer maintains Outperform on CalciMedica stockMay 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CalciMedica (CALC) and GE Healthcare Technologies Inc (GEHC)May 14, 2024 | finanznachrichten.deCalciMedica, Inc.: CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate UpdatesMay 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for CalciMedica Backed by Strong Financials and Promising Clinical TrialsMay 13, 2024 | prnewswire.comCalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate UpdatesMay 7, 2024 | prnewswire.comCalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024April 24, 2024 | prnewswire.comCalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute PancreatitisSee More Headlines Receive CALC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CalciMedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/27/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CALC CUSIPN/A CIK1534133 Webwww.graybug.vision Phone858-952-5500FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Target$20.67 High Stock Price Target$22.00 Low Stock Price Target$20.00 Potential Upside/Downside+424.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-143.95% Return on Assets-102.67% Debt Debt-to-Equity RatioN/A Current Ratio6.21 Quick Ratio6.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book2.77Miscellaneous Outstanding Shares10,750,000Free Float5,020,000Market Cap$42.36 million OptionableNo Data Beta1.28 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. A. Rachel Leheny Ph.D. (Age 61)CEO & Director Comp: $852.84kMr. Eric W. Roberts (Age 60)Chief Business Officer & Vice Chairman of the Board Comp: $757.4kDr. Kenneth A. Stauderman Ph.D. (Age 71)Co-Founder & Chief Scientific Officer Comp: $615.59kMr. Michael J. Dunn M.B.A. (Age 68)MBA, President & COO Dr. Anjana Rao Ph.D.Co-Founder and Scientific AdvisorDr. Patrick Hogan Ph.D.Co-Founder and Scientific AdvisorDr. Stefan Feske M.D.Co-Founder and Scientific AdvisorMr. Daniel E. Geffken M.B.A. (Age 67)Interim Chief Financial Officer Cindy ReiedenbergAccountantMr. John M. Dunn J.D. (Age 72)General Counsel More ExecutivesKey CompetitorsCara TherapeuticsNASDAQ:CARAVaccinexNASDAQ:VCNXOrganigramNASDAQ:OGIRepare TherapeuticsNASDAQ:RPTXSyros PharmaceuticalsNASDAQ:SYRSView All CompetitorsInsidersRobert N WilsonBought 8,443 shares on 6/27/2024Total: $27,270.89 ($3.23/share)Eric W RobertsBought 5,000 shares on 6/27/2024Total: $16,100.00 ($3.22/share)Eric W RobertsBought 746 shares on 4/1/2024Total: $2,909.40 ($3.90/share)Fred A MiddletonBought 679,384 shares on 1/23/2024Total: $2.51 M ($3.70/share)Sanderling Venture Partners ViBought 243,356 shares on 1/23/2024Total: $900,417.20 ($3.70/share)View All Insider Transactions CALC Stock Analysis - Frequently Asked Questions How have CALC shares performed this year? CalciMedica's stock was trading at $2.86 at the beginning of 2024. Since then, CALC stock has increased by 37.8% and is now trading at $3.94. View the best growth stocks for 2024 here. How were CalciMedica's earnings last quarter? CalciMedica, Inc. (NASDAQ:CALC) issued its quarterly earnings results on Monday, May, 13th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.07. How do I buy shares of CalciMedica? Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CALC) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
